Drug intelligence / Profile preview

RAB-008a

Development stage: Preclinical
Lead developer: Zhongshan Laibo Ruichen Biopharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

RAB-008a is an orally administered small molecule drug candidate currently in preclinical development by **ZhongShan LaiBo RuiChen BioMedicine** (also known as **RabPharma**). It is specifically being developed for the treatment of **bone metastasis**, a condition where cancer cells spread from a primary tumor to the bone. As part of a pipeline focused on bone and joint health, RAB-008a is designed to provide a convenient oral therapeutic option for managing metastatic bone disease. While its specific molecular target and mechanism of action have not been publicly disclosed, it is categorized as a small molecule therapeutic within the company's oncology-related bone health portfolio.

Beyond the preview

Go deeper on RAB-008a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RAB-008a.

Explore the full profile